Combretastatin A4-phosphate and its potential in veterinary oncology: a review

Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trial.

(2017) E. B. Garon et al.   JOURNAL OF CLINICAL ONCOLOGY

Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic

(2013) MARLEIN MIRANDA CONA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma

(2013) Julie A. Sosa et al.   THYROID

Sequential Systemic Administrations of Combretastatin A4 Phosphate and Radioiodinated Hypericin Exert Synergistic Targeted Theranostic Effects with Prolonged Survival on SCID Mice Carrying Bifocal Tumor Xenografts

(2013) Junjie Li et al.   Theranostics

Exploring Theranostic Potentials of Radioiodinated Hypericin in Rodent Necrosis Models

(2012) Junjie Li et al.   Theranostics

Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck

(2011) Q.- S. Ng et al.   ANNALS OF ONCOLOGY

Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature

(2011) Tingyuan Yang et al.   Nanomedicine-Nanotechnology Biology and Medicine

A Dual-targeting Anticancer Approach: Soil and Seed Principle

(2011) Junjie Li et al.   RADIOLOGY

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin and paclitaxel in patients with advanced cancer

(2010) G J Rustin et al.   BRITISH JOURNAL OF CANCER

The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents

(2010) Dietmar W. Siemann   CANCER TREATMENT REVIEWS

Combretastatin-induced hypertension and the consequences for its combination with other therapies

(2010) Morten Busk et al.   VASCULAR PHARMACOLOGY

Angiogenesis in asthma

(2009) D. Ribatti et al.   CLINICAL AND EXPERIMENTAL ALLERGY

A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)

(2009) Dietmar W Siemann et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Treatment of Rodent Liver Tumor With Combretastatin A4 Phosphate

(2009) Huaijun Wang et al.   INVESTIGATIVE RADIOLOGY

Development of a rapid and sensitive LC–MS/MS assay for the determination of combretastatin A4 phosphate, combretastatin A4 and combretastatin A4 glucuronide in beagle dog plasma and its application to a pharmacokinetic study

(2009) Xiaojing Wang et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome

(2009) Colin J. Mooney et al.   THYROID

Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats

(2009) Qingen Ke et al.   VASCULAR PHARMACOLOGY

Angiogenesis and obesity

(2007) H. R. Lijnen   CARDIOVASCULAR RESEARCH